IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma

Histopathology

Volumn 58, Issue 5, 2011, Pages 729-738

  Sugita, Shintaro ^a,b   Morishita, Yukio ^a,b   Kano, Junko ^a   Furuya, Shuichiro ^b   Shiba Ishii, Aya ^a   Noguchi, Masayuki ^a,b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA HOSPITAL   (Japan)

Author keywords

Clear cell adenocarcinoma; HNF 1 ; IGFBP 1; Immunohistochemistry; In situ hybridization

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 1BETA; MESSENGER RNA; SOMATOMEDIN BINDING PROTEIN 1;

ADULT; AGED; ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DECIDUA; ENDOMETRIUM; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SPECIFICITY;

ADENOCARCINOMA, CLEAR CELL; ADULT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MIDDLE AGED; OVARIAN NEOPLASMS; RNA, MESSENGER;

ANAS;

EID: 79954504786     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03817.x     Document Type: Article

References (22)

1. Yamada K, Kano J, Tsunoda H et al. Phenotypic characterization of endometrial stromal sarcoma of the uterus. Cancer Sci. 2006; 97; 106-112.
2. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995; 16; 3-34.
3. Druckmann R, Rohr UD. IGF-1 in gynaecology and obstetrics: update 2002. Maturitas 2002; 41(Suppl. 1); S65-S83.
4. Fowler DJ, Nicolaides KH, Miell JP. Insulin-like growth factor binding protein-1 (IGFBP-1): a multifunctional role in the human female reproductive tract. Hum. Reprod. Update 2000; 6; 495-504.
5. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003; 195; 127-137.
6. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J. Natl. Cancer Inst. 2000; 92; 1472-1489.
7. Hirano S, Ito N, Takahashi S, Tamaya T. Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur. J. Gynaecol. Oncol. 2004; 25; 187-191.
8. Wang H, Rosen DG, Wang H, Fuller GN, Zhang W, Liu J. Insulin-like growth factor-binding proteins 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod. Pathol. 2006; 19; 1149-1156.
9. Lancaster JM, Sayer RA, Blanchette C et al. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int. J. Gynecol. Cancer 2006; 16; 1529-1535.
10. Tsuchiya A, Sakamoto M, Yasuda J et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 2003; 163; 2503-2512.
11. Powell DR, Suwanichkul A. HNF1 activates transcription of the human gene for insulin-like growth factor binding protein-1. DNA Cell Biol. 1993; 12; 283-289.
12. Suh DS, Rechler MM. Hepatocyte nuclear factor 1 and the glucocorticoid receptor synergistically activate transcription of the rat insulin-like growth factor binding protein-1 gene. Mol. Endocrinol. (Balt.) 1997; 11; 1822-1831.
13. Kato N, Sasou S, Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod. Pathol. 2006; 19; 83-89.
14. Pei Y, Kano J, Iijima T, Morishita Y, Inadome Y, Noguchi M. Overexpression of Dickkopf 3 in hepatoblastomas and hepatocellular carcinomas. Virchows Arch. 2009; 454; 639-646.
15. Inaba N, Ishige H, Ijichi M et al. Immunohistochemical detection of pregnancy-specific protein (SP1) and placenta-specific tissue proteins (PP5, PP10, PP11 and PP12) in ovarian adenocarcinomas. Oncodev. Biol. Med. 1982; 3; 379-389.
16. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF, Langdon SP. Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin. Cancer Res. 2007; 13; 1438-1444.
17. Kobel M, Xu H, Bourne PA et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod. Pathol. 2009; 22; 469-475.
18. Kato N, Motoyama T. Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology 2008; 52; 682-688.
19. Higashiguchi A, Yamada T, Susumu N et al. Specific expression of hepatocyte nuclear factor-1beta in the ovarian clear cell adenocarcinoma and its application to cytological diagnosis. Cancer Sci. 2007; 98; 387-391.
20. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and non-neoplastic endometrium. Hum. Pathol. 2007; 38; 1074-1080.
21. Vang R, Barner R, Wheeler DT, Strauss BL. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial Arias-Stella reaction from high-grade carcinoma, including clear cell carcinoma. Int. J. Gynecol. Pathol. 2004; 23; 223-233.
22. Nucci MR, Young RH. Arias-Stella reaction of the endocervix: a report of 18 cases with emphasis on its varied histology and differential diagnosis. Am. J. Surg. Pathol. 2004; 2; 608-612.